The EHA Research Roadmap: Transfusion Medicine

Simon J. Stanworth, Anneke Brand, Srini, V Kaveri, Hans Vrielink, Andreas Greinacher, Dragoslav Domanovic, Marieke von Lindern, Shubha Allard, Jagadeesh Bayry, Milos Bohonek, Andreas Buser, Frans H. J. Claas, Folke Knutson, Miguel Lozano, Martin L. Olsson, France Pirenne, Paolo Rebulla, Cynthia So-Osman, Jean-Daniel Tissot, Ashley M. ToyeInes Ushiro-Lumb, Emile van den Akker, Sacha Zeerleder

Research output: Contribution to journalEditorialAcademicpeer-review

3 Citations (Scopus)
26 Downloads (Pure)

Abstract

In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1-2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including eleven sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell-based Immune Therapies; and Gene Therapy.

Original languageEnglish
Pages (from-to)E670
JournalHemaSphere
Volume6
Issue number2
DOIs
Publication statusPublished - 25 Feb 2022

Bibliographical note

Funding Information:
SJS is employed in NHSBT. SVK is a Jury Member for the evaluation of CSL Behring France “Fonds de dotation” scholarships; a Jury Member for the evaluation of E-SPIN awards from Grifols. HV is employed by Sanquin Blood Supply (NL). AG received personal fees from Aspen, Bayer Vital, Chromatec, Instrumentation Laboratory, Macopharma, Sanofi-Aventis, Roche, GTH e.V; grants from Ergomed, Boehringer Ingelheim, Sagent, Macopharma, Portola, Biokit, Fa. Blau Farmaceutics, Prosensa/Biomarin, DRK-BSD NSTOB, DRK-BSD Baden-Würtemberg/Hessen; and patent modified SARS CoV 2 vaccine pending. MvL is employed by Sanquin Blood Supply (NL). JB received research grant from CSL Behring France. FHJC is a scientific advisor of GenDx and Immucor. ML received research support from TerumoBCT and royalties of payments from Grífols. PR is consulting for Meditalia srl and a Founder and shareholder of Episkey srl. IUL is consulting for Roche Diagnostics. SZ received unrestricted grant JAZZ Pharma and speakers fees from Sanofi and Takeda. AMT's salary and research is funded by NHSBT. All the other authors have no conflicts of interest to disclose.

Publisher Copyright:
© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. HemaSphere (2022) 6:2(e670).

Fingerprint

Dive into the research topics of 'The EHA Research Roadmap: Transfusion Medicine'. Together they form a unique fingerprint.

Cite this